Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026)
Hims & Hers Health (HIMS) posted Cash from Investing Activities of -$15.4 million for Q1 2026, up 81.54% sequentially from -$83.7 million in Q4 2025, and up 52.9% YoY from -$10.1 million in Q1 2025.
Hims & Hers Health (HIMS) Cash from Investing Activities (2019 - 2026) Analysis & Trends
Hims & Hers Health has reported Cash from Investing Activities for 8 years, with the latest figure at -$15.4 million in Q1 2026.
- Quarterly Cash from Investing Activities rose 52.9% year-over-year to -$15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (down 1452.89% YoY) and the FY2025 annual result came in at -$1.0 billion, down 5280.92% from the prior year.
- Cash from Investing Activities climbed to -$15.4 million in Q1 2026 per HIMS's latest filing, from -$83.7 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $20.7 million in Q4 2023 and troughed at -$887.4 million in Q3 2025.
- A 5-year average of -$61.0 million and a median of -$4.5 million in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities soared 417.09% in 2024, then slumped 8421.2% in 2025.
- Over 5 years, Cash from Investing Activities stood at $6.0 million in 2022, then surged by 244.74% to $20.7 million in 2023, then tumbled by 183.14% to -$17.2 million in 2024, then plunged by 386.32% to -$83.7 million in 2025, then jumped by 81.54% to -$15.4 million in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$15.4 million, -$83.7 million, and -$887.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | -491.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | -300.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | -550.24 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 87.50 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | -51.60 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | -135.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | -110.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Hims & Hers Health | 7.42 Bn | 6.57 Bn | 480.80 Mn | 84.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.54 Mn |
| Jun 30, 2026 | 84.54 Mn |
| Mar 31, 2026 | -15.45 Mn |
| Mar 31, 2026 | -15.45 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Dec 31, 2025 | -83.68 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Sep 30, 2025 | -887.40 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Jun 30, 2025 | -21.09 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Mar 31, 2025 | -32.80 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Dec 31, 2024 | -17.21 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Sep 30, 2024 | -10.41 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Jun 30, 2024 | -4.47 Mn |
| Mar 31, 2024 | 13.04 Mn |
| Mar 31, 2024 | 13.04 Mn |